In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Ironwood Pharmaceuticals, Inc.. Trade Record

NASDAQ:IRWD Ironwood Pharmaceuticals, Inc. stock gains 6.06% Exit May 30, 2017 a Trade Record by priceseries

Trade Chart
Trade Chart IRWD May 9, 2017, priceSeries
About Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Constella name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout under ZURAMPIC and DUZALLO names. It has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in North America, China, Hong Kong, and Macau; and license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, chronic constipation, and other GI conditions in Japan. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.

Trade Information
Trade Type
LONG
ReliabilityScore™
97.32
Entry Date
May 9, 2017
Entry Price
14.19
Sell Date
May 30, 2017
Sell Price
15.05
Net Gain
6.06%
Hold Time
14 Trading Days